US2020157535A1PendingUtilityA1

Methods and compositions for modulating alpha-1-antitrypsin expression

Assignee: IONIS PHARMACEUTICALS INCPriority: Mar 19, 2012Filed: Jun 26, 2019Published: May 21, 2020
Est. expiryMar 19, 2032(~5.6 yrs left)· nominal 20-yr term from priority
C12N 2310/315A61K 31/7125C12N 15/113C12N 2310/3341C12N 2310/3233C12N 2310/341A61K 31/712A61K 31/7115C07K 14/8125C12N 2310/11C12N 2310/3231C12N 2310/346C12N 2310/321
74
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed herein are methods for decreasing A1AT mRNA and protein expression and treating, ameliorating, preventing, slowing progression, or stopping progression of fibrosis. Disclosed herein are methods for decreasing A1AT mRNA and protein expression and treating, ameliorating, preventing, slowing progression, or stopping progression of liver disease, such as, A1ATD associated liver disease, and pulmonary disease, such as, A1ATD associated pulmonary disease in an individual in need thereof. Methods for inhibiting A1AT mRNA and protein expression can also be used as a prophylactic treatment to prevent individuals at risk for developing a liver disease, such as, A1ATD associated liver disease and pulmonary disease, such as, A1ATD associated pulmonary disease.

Claims

exact text as granted — not AI-modified
1 - 3 . (canceled) 
     
     
         4 . A compound comprising a modified oligonucleotide consisting of 20 to 30 linked nucleosides and having a nucleobase sequence comprising a portion of at least 20 contiguous nucleobases that is 100% complementary to an equal length portion of nucleobases 1349 to 1597 of SEQ ID NO: 1, and wherein the nucleobase sequence of the modified oligonucleotide is at least 90% complementary to SEQ ID NO: 1, and wherein each nucleotide of the modified oligonucleotide is a modified nucleotide having, independently, a modified sugar moiety, a modified internucleoside linkage, and/or modified nucleobase. 
     
     
         5 - 23 . (canceled) 
     
     
         24 . A composition comprising a compound according to  claim 4  and a pharmaceutically acceptable carrier or diluent. 
     
     
         25 . (canceled) 
     
     
         26 . A method of treating, ameliorating or preventing an A1AT deficiency disease in an animal comprising administering to an animal having or at risk of developing an A1AT deficiency disease a composition according to  claim 24 , and thereby treating, ameliorating, or preventing the A1AT deficiency disease in the animal. 
     
     
         27 - 49 . (canceled)

Join the waitlist — get patent alerts

Track US2020157535A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.